|
Summary of specific antisera and immunohistochemistry conditions |
|||||
| Protein |
Antibody |
Dilution & incubation |
Antigen pretreatment |
Positive control |
Stain |
|
|
|||||
| Cyclin D1 |
P2D11F11 Novocastra |
1:50 |
Microwave |
Colon cancer |
Nuclear |
| Cyclin E |
13A3 Novocastra |
1:80 |
Microwave |
Breast cancer |
Nuclear |
| CDK4 |
C-22 Santa Cruz Biotechnology |
1:300 |
Microwave |
Colon cancer |
Nuclear |
| P53 |
DO7 DAKO |
1:50, 2 h |
Microwave |
Breast cancer |
Nuclear |
| P21waf |
SX118, DAKO |
1:50, 2 h |
Microwave |
Epidermis |
Nuclear |
| Mdm-2 |
Monoclonal IF2 Oncogene |
1:20, 2 h |
Microwave |
sarcoma |
Nuclear |
| P27 |
SX53G8, DAKO |
1:80, 1 h |
None |
Breast cancer |
Nuclear |
| P16 |
6H12 Novocastra Lab |
1:40 |
Microwave |
Epidermis |
Nuclear |
| Rb |
Rb1(recognizes phosphorylated & non-phosphorylated protein) DAKO |
1:80 |
Microwave |
Retinoblastoma |
Nuclear |
| Ki-67 |
MIB 1, Dako |
1:50 |
Microwave |
Breast cancer |
Nuclear |
Bahnassy et al. BMC Clinical Pathology 2007 7:4 doi:10.1186/1472-6890-7-4 |
|||||